SCHEMBL15214058

SCHEMBL15214058

COc1ncc(C)cc1-c1cnc(NC(=O)c2c(F)cncc2F)cn1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ IL2 P60568 13/20 0.50
▸ STIM1 Q13586 1/20 0.41
▸ ORAI1 Q96D31 1/20 0.41
▸ ORAI2 Q96SN7 1/20 0.41
▸ HCRTR2 O43614 4/20 0.37
▸ HCRTR1 O43613 3/20 0.37
▸ NPC1 O15118 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ GLA P06280 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15214056 0.90 IL2 (0.54) IL2STIM1ORAI1ORAI2NPC1
SCHEMBL5550482 0.88 IL2 (0.47) IL2STIM1ORAI1ORAI2NPC1
SCHEMBL5556128 0.88 IL2 (0.47) IL2STIM1ORAI1ORAI2NPC1
SCHEMBL15214057 0.86 IL2 (0.54) IL2STIM1ORAI1ORAI2NPC1
SCHEMBL8258488 0.85 IL2 (0.47) IL2STIM1ORAI1ORAI2RAB9A
SCHEMBL15395991 0.84 IL2 (0.56) IL2STIM1ORAI1ORAI2NPC1
SCHEMBL5554212 0.81 IL2 (0.50) IL2STIM1ORAI1ORAI2
SCHEMBL15395925 0.81 IL2 (0.65) IL2STIM1ORAI1ORAI2NPC1
SCHEMBL5554217 0.81 IL2 (0.49) IL2STIM1ORAI1ORAI2
SCHEMBL15395779 0.79 STIM1 (0.53) IL2STIM1ORAI1ORAI2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8518950-B2 pyrazinyl, pyrimidinyl and pyridazinyl derivatives such asN-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-2,6-difluoro-benzamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-08-27 — — US disclosed
Send feedback